Anbarasan Sekar

Anbarasan Sekar

Auto-generated profile, based on publicly available information

Anbarasan Sekar

Department of Medical Oncology, Tata Memorial Centre, Mumbai, Maharashtra, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 April 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
MSMinit Shah
Minit Shah
SRSushmita Rath
Sushmita Rath
SGSeema Gulia
Seema Gulia
PBPrabhat Bhargava
Prabhat Bhargava
ASAnbarasan Sekar
Anbarasan Sekar
SGSudeep Gupta
Sudeep Gupta
PURPOSE: There are scant data on patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer treated with neoadjuvant therapy (NAT) in real-world settings with limited access to HER2-targeted therapy. METHODS: This was a retrospective analysis of patients with nonmetastatic, HER2-positive breast cancer treated with NAT between January 2014 and December 2018 to determine factors affecting pathologic complete response (pCR), event-free survival (EFS), and overall survival (OS). RESULTS: The cohort comprised 1,004 patients with a median age of 47 years, 533 (53.1%) with clinical T3/T4 tumors, 466 (46.4%) with clinical N2/3 status, and 527 (52.5%) with hormone receptor–positive disease. Trastuzumab was given to 528 (52.6%) patients in the neoadjuvant setting and 711 (70.8%) patients in neoadjuvant and/or postoperative settings. pCR was achieved in 226 (22.5%) patients; the 5-year EFS in the whole cohort, pCR group, and no-pCR group was 63.5% (95% CI, 60.36 to 66.63), 86.1% (95% CI, 81.59 to 90.60), and 57% ([95% CI, 53.47 to 60.52]; P < .001), respectively. In multivariable analysis in the full cohort, smaller tumor size (cT1/T2 v cT3/T4), higher grade (III v II), hormone receptor–negative status, and use of neoadjuvant HER2-targeted therapy were significantly associated with higher pCR, and smaller tumor size (cT1/T2 v cT3/T4), lower node involvement (cN0/N1 v cN2/N3), achievement of pCR, and receiving trastuzumab were significantly associated with higher EFS and OS. CONCLUSION: In a setting with constrained access to HER2-targeted therapy, lower clinical tumor burden and receiving trastuzumab were significantly associated with increased pCR and survival in patients with HER2-positive breast cancer treated with NAT. Efforts should be made to enhance early diagnosis and access to HER2-targeted therapy worldwide.

1 April 2026 in Indian Journal of Cancer
Verified
Journal Article
Open access
AMAnuradha Mehta
Anuradha Mehta
DSDebdeep Samaddar
Debdeep Samaddar
PBPrabhat Bhargava
Prabhat Bhargava
ASAnbarasan Sekar
Anbarasan Sekar
GJGeorge John
George John
SRSushmita Rath
Sushmita Rath
Background: Hormone receptor-positive (HR+)/HER2-negative (HER2−) early breast cancer (EBC) is associated with a persistent risk of recurrence despite optimal local therapy and adjuvant endocrine therapy, particularly in patients with high-risk clinicopathologic features. Adjuvant cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated significant benefits in randomized clinical trials; however, real-world data from Indian populations remain limited. This study evaluates real-world outcomes, tolerability, and treatment adherence to adjuvant CDK4/6 inhibitors in HR+/HER2 − EBC patients treated at a tertiary cancer center in India. Methods: This single-center, retrospective observational study included consecutive adult patients with HR+/HER2 − EBC who received adjuvant endocrine therapy in combination with either ribociclib or abemaciclib following definitive surgery between January 2023 and December 2025. Demographic, clinicopathologic, treatment, toxicity, and outcome data were extracted from institutional medical records. Adverse events were graded using common terminology criteria for adverse events. The primary endpoints were treatment tolerability and invasive disease-free survival (iDFS). Secondary endpoints included overall survival, dose modifications, and treatment discontinuation rates. Survival outcomes were estimated using the Kaplan–Meier method. Results: A total of 75 patients (median age: 52 years) were analyzed. Stage III disease was present in 69.3% of patients, including IIIA/IIIB/IIIC, and ≥4 positive lymph nodes were observed in 70.6%, representing a high-risk group. Node-negative status was seen in 10 (13.3%) patients. Ribociclib was administered to 55.3% of patients and abemaciclib to 43.4% of patients, and dose modifications were required in 14.2% and 18.1% of patients, respectively, while permanent discontinuation occurred in 3.6% of ribociclib-treated patients and none in the abemaciclib group. Grade ≥3 toxicities were infrequent. In the ribociclib group, grade 3–4 neutropenia occurred in 6.0%, anemia in 4.7%, thrombocytopenia in 2.3%, and diarrhea in 2.3% of patients. In the abemaciclib group, grade 3–4 neutropenia was observed in 6.0%, anemia in 3.0%, thrombocytopenia in 3.0%, and diarrhea in 12.1%, the latter being the most frequent severe adverse event. At a median follow-up of 6.35 months, iDFS was 100% at 6 months and 90.6% at 12 months. Conclusion: In this real-world Indian cohort, adjuvant CDK4/6 inhibitors demonstrated favorable tolerability, low rates of severe toxicity and permanent discontinuation, and encouraging early disease control in high-risk HR+/HER2 − EBC patients. These findings support the feasibility and applicability of adjuvant CDK4/6 inhibitor therapy in routine clinical practice in India, while emphasizing the need for longer follow-up and larger multicenter studies.

17 February 2022 in Research Square
Verified
Preprint
Open access
PDF file
ASAnbarasan Sekar
Anbarasan Sekar
VNVanita Noronha
Vanita Noronha
ARAkhil Rajendra
Akhil Rajendra
SMSmruti Mokal
Smruti Mokal
VPVijay Patil
Vijay Patil
RBRajendra Badwe
Rajendra Badwe
Background: There has been a definite change in the histopathological spectrum of esophageal cancer towards adenocarcinoma seen in developed countries. In India such studies were limited. Materials and Methods: We retrospectively evaluated patients with histologically proven esophageal cancer who were registered at the Tata Memorial Hospital (Mumbai, India) between 2003 and 2018. The primary aim was to analyze the time-trend of the histological pattern of esophageal cancer. Our secondary objectives included evaluating whether there was any correlation between age, sex, demographics, socioeconomic status, the presence of comorbidities and substance abuse and the histological type of esophageal cancer. Results: Among 7874 patients with esophageal cancer, 5092 (64.7%) were men, with M:F of 2.5:1. The median age was 57 years (IQR, 50-65); Of the 4912 patients in whom a history of tobacco or alcohol use had been elicited, 1360 (27.7%) patients denied substance abuse. Majority of tumor was in middle-third 2942 (41.5%). Squamous cell carcinoma was the histological type in 6413 (81.4%) patients. Multivariate analysis showed that female sex and substance abuse were positively associated with squamous cell carcinoma, while the presence of comorbidities and location of the primary in lower esophagus/GEJ were positively associated with adenocarcinoma. Conclusions: There is no evidence of an epidemiologic shift in the histopathologic spectrum of esophageal cancer in India over last two decades. Four out of five Indian patients with esophageal cancer have squamous cell histology. This is important to recognize, given the varying molecular spectrum and efficacy of therapeutic modalities based on histopathology.